Xtandi and Central nervous system lesion - a phase IV clinical study of FDA data

Summary:

Central nervous system lesion is reported as a side effect among people who take Xtandi (enzalutamide), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Xofigo, and have Prostate cancer metastatic.

The phase IV clinical study analyzes which people have Central nervous system lesion when taking Xtandi. It is created by eHealthMe based on reports of 51,433 people who have side effects when taking Xtandi from the FDA, and is updated regularly.

What is Xtandi?

Xtandi has active ingredients of enzalutamide. eHealthMe is studying from 51,498 Xtandi users. Check the latest studies of Xtandi.

What is Central nervous system lesion?

Central nervous system lesion (an abnormality in tissue of brain or spinal cord) is found to be associated with 779 drugs and 824 conditions by eHealthMe. Check the latest studies of Central nervous system lesion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

51,433 people reported to have side effects when taking Xtandi.
Among them, 22 people (0.04%) have Central nervous system lesion.

Could Xtandi cause Central nervous system lesion?

Among these 22 people:

How long have people been on Xtandi when they have Central nervous system lesion? *

What is the gender of people who have Central nervous system lesion when taking Xtandi? *

female: 0.0 %
male: 100 %

What is the age of people who have Central nervous system lesion when taking Xtandi? *

What are other drugs people take besides Xtandi? *

What are other side effects people have besides Central nervous system lesion? *

Vision Blurred: 16 people, 72.73%
Hyphaema (collection of blood inside the front part of the eye): 16 people, 72.73%
Prostatic Specific Antigen Increased: 13 people, 59.09%
Pigmentary Glaucoma (affliction of the eye that can lead to a form of glaucoma): 13 people, 59.09%
Cyclitis (inflammation of the ciliary body (eye)): 11 people, 50.00%
Intraocular Pressure Increased: 10 people, 45.45%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 8 people, 36.36%
Iridocyclitis (inflammation of the iris and ciliary body of the eye): 8 people, 36.36%
Malignant Neoplasm Progression (cancer tumour came back): 7 people, 31.82%
Glaucoma (increased fluid pressure in the eye with vision loss): 5 people, 22.73%

What are the existing conditions these people have? *

Prostate Cancer Metastatic: 17 people, 77.27%
Prostate Cancer: 4 people, 18.18%
Bone Disorder: 2 people, 9.09%
Neoplasm Prostate (tumour of prostate): 1 person, 4.55%
High Blood Cholesterol: 1 person, 4.55%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Xtandi and have Central nervous system lesion?

- Check whether Central nervous system lesion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xtandi:

Xtandi (51,498 reports)

Browse all side effects of Xtandi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Central nervous system lesion:

Central nervous system lesion (779 drugs)

Browse all the conditions that are associated with Central nervous system lesion:

Central nervous system lesion (824 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on enzalutamide (the active ingredients of Xtandi) and Xtandi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.